Author: Judith Wenshuk

By Judith Wenshuk, peptide research writer

Quick Answer: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell, essential to energy production and DNA repair processes. Levels decline naturally with age, which is the central reason it’s drawn so much research interest in aging and cellular-energy research.

NAD+ isn’t a peptide in the strict sense — it’s a coenzyme — but it’s grouped alongside research peptides because of shared research interest in cellular health and aging. It’s available in Canada through research peptide suppliers for laboratory study.

What NAD+ Does

NAD+ is involved in hundreds of metabolic processes, most notably as a critical component of mitochondrial energy production — the process that converts nutrients into usable cellular energy. It’s also involved in DNA repair and cellular signaling pathways linked to aging research.

Why NAD+ Declines With Age

Research has consistently shown NAD+ levels decrease as people age, and this decline is one of the more well-established findings connecting cellular aging to measurable biochemical change. This is the central reason NAD+ research has expanded so significantly in longevity and cellular-health research contexts.

What It’s Studied For

• Cellular energy production research — its core, most fundamental role
• Aging and longevity research — tied directly to its natural age-related decline
• DNA repair pathway research — a less publicized but well-documented area of NAD+ activity

Frequently Asked Questions

Is NAD+ actually a peptide? No — it’s a coenzyme, not a peptide, but it’s commonly grouped with research peptides due to overlapping research interest in cellular health.

Why does NAD+ decline with age? The exact mechanisms are still an active area of research, but the decline itself is a consistently observed finding across studies.

Is NAD+ available as a research compound in Canada? Yes — NAD+ is available through research peptide suppliers in Canada as a laboratory research compound.

By Judith Wenshuk, peptide research writer

Quick Answer: BPC-157 and TB-500 are the two most-referenced compounds in recovery-focused research, often studied together but with distinct mechanisms — BPC-157 is a gastric-derived peptide with broad tissue-repair research, while TB-500 relates to actin regulation and cell migration. They’re commonly used together rather than as a strict either/or choice.

If you’re researching tissue repair and recovery, these are the two names you’ll run into constantly, usually mentioned in the same breath. Here’s what actually separates them.

BPC-157: What It’s Studied For

BPC-157 (Body Protection Compound-157) is derived from a protective protein found in gastric juice, and it has the broadest research base of the two — spanning tendon and ligament healing, gut and digestive tract research, and general soft-tissue repair. It’s the most-referenced single compound in this entire research category.

TB-500: What It’s Studied For

TB-500 is a synthetic fragment related to Thymosin Beta-4, a naturally occurring protein involved in cell migration and actin regulation — the cellular scaffolding involved in tissue structure and movement. Its research focus centers more specifically on muscle tissue and broader systemic recovery, compared to BPC-157’s more concentrated focus on tendons, ligaments, and gut tissue.

Key Differences

• Origin: BPC-157 is derived from a gastric protective protein; TB-500 is a synthetic fragment of a naturally occurring cell-regulation protein
• Primary research focus: BPC-157 leans toward tendon/ligament/gut research; TB-500 leans toward muscle tissue and systemic recovery
• Research volume: BPC-157 has a larger and longer-standing body of published research

Why They’re Often Combined

Rather than choosing one over the other, much of the research community treats BPC-157 and TB-500 as complementary — the reasoning being that their differing mechanisms and focus areas make them cover more ground together than either compound alone. This is reflected in blends like GLOW and KLOW, both of which include both compounds alongside others.

Frequently Asked Questions

Is one more effective than the other? They’re not directly interchangeable — their research focuses differ enough that “more effective” depends entirely on the specific research application.

Can BPC-157 and TB-500 be reconstituted the same way? Yes — both follow the same standard reconstitution process covered in our step-by-step guide.

Are BPC-157 and TB-500 available as research compounds in Canada? Yes — both are available individually, or combined in blends like GLOW and KLOW, through research peptide suppliers in Canada.

By Judith Wenshuk, peptide research writer

Quick Answer: CJC-1295 and Ipamorelin are two growth-hormone-secretagogue compounds studied together because they work through complementary mechanisms — CJC-1295 extends growth hormone release duration, while Ipamorelin triggers a cleaner pulse of release. Together, they’re one of the most commonly paired combinations in growth-hormone research.

Among growth-hormone-related research peptides, this specific pairing shows up more than almost any other combination, and there’s a real mechanistic reason for that rather than just habit.

How Each Compound Works

CJC-1295 is a GHRH analogue — similar in category to Tesamorelin — that extends the duration of growth hormone release once triggered. Ipamorelin is a ghrelin-receptor agonist that triggers growth hormone release itself, and is generally regarded as one of the “cleaner” compounds in its category because it’s more selective for growth hormone release without significantly affecting cortisol or other hormones the way some older secretagogues do.

Why They’re Paired

The reasoning behind combining them is straightforward: Ipamorelin triggers the release, and CJC-1295 extends how long that release lasts. Used together, research interest centers on whether this produces a more sustained growth hormone signaling profile than either compound would on its own.

CJC-1295: No DAC vs. With DAC

Worth knowing if you’re comparing products: CJC-1295 is available in two forms. “No DAC” has a shorter half-life and is the form typically paired with Ipamorelin for a more defined release pattern. The DAC version has an extended half-life, which changes the dosing frequency and research application. Most CJC/Ipamorelin blends use the No DAC version specifically.

How It Compares to Other Growth-Hormone Compounds

If you’re deciding between this pairing and Tesamorelin specifically, or want the full picture including HGH itself, we’ve written both comparisons.

Frequently Asked Questions

Is CJC-1295/Ipamorelin the same as taking HGH directly? No — both compounds work by stimulating the body’s own growth hormone release rather than supplying growth hormone directly, which is the core difference from HGH itself.

Why does Ipamorelin have a reputation as “cleaner” than other secretagogues? It’s more selective for growth hormone release specifically, with less research-reported impact on cortisol and other hormones compared to some older-generation compounds in the same category.

Is this combination available as a research compound in Canada? Yes — CJC-1295 and Ipamorelin are available individually or as a pre-combined blend through research peptide suppliers in Canada.

By Judith Wenshuk, peptide research writer

Quick Answer: IGF-1 LR3 is a long-acting analogue of insulin-like growth factor 1, studied for its role downstream of growth hormone activity — specifically in muscle tissue growth and cellular repair. The “LR3” modification extends its activity duration significantly compared to natural IGF-1, which is the main reason the research variant exists.

IGF-1 LR3 sits one step downstream from the growth-hormone-secretagogue compounds like CJC-1295 and Ipamorelin — where those compounds stimulate growth hormone release, IGF-1 LR3 relates to what growth hormone actually triggers in the body afterward. It’s available in Canada through research peptide suppliers for laboratory study.

How It Works

Growth hormone doesn’t act directly on muscle tissue — much of its effect is mediated through IGF-1, which the liver produces in response to growth hormone signaling. IGF-1 LR3 is a modified, longer-acting version of this naturally occurring factor: the “LR3” (Long Arg3) modification changes its binding affinity to proteins that would normally clear it from the body quickly, extending its active window from roughly 20-30 minutes (natural IGF-1) to closer to 20-30 hours.

What It’s Studied For

• Muscle tissue growth research — as a downstream effector of the growth hormone pathway
• Cellular repair and recovery — IGF-1 signaling is involved in broader tissue repair processes, not muscle alone
• Research into growth hormone pathway effects — since IGF-1 LR3 lets researchers study effects further downstream than the secretagogues themselves

How It Differs From Growth-Hormone Secretagogues

Compounds like CJC-1295, Ipamorelin, and Tesamorelin all work by increasing the body’s own growth hormone release. IGF-1 LR3 is different — it doesn’t affect growth hormone release at all. Instead, it acts on the pathway that growth hormone itself triggers, which is why some research protocols combine a secretagogue with IGF-1 LR3 rather than treating them as substitutes for each other.

Frequently Asked Questions

Is IGF-1 LR3 the same as growth hormone? No — it acts downstream of growth hormone, in the pathway growth hormone itself activates, rather than being growth hormone.

Why “LR3” specifically, instead of natural IGF-1? The LR3 modification dramatically extends how long it stays active, which is the entire reason the research variant exists over natural IGF-1’s very short window.

Is IGF-1 LR3 available as a research compound in Canada? Yes — IGF-1 LR3 is available through research peptide suppliers in Canada as a laboratory research compound.

By Judith Wenshuk, peptide research writer

Quick Answer: GHK-Cu is a copper peptide studied for its role in skin repair, collagen production, and wound healing research. It’s one of the most established compounds in cosmetic and dermatological research, but it comes with a well-known cosmetic side effect nicknamed “copper uglies” — temporary skin discoloration and flushing at the injection or application site.

GHK-Cu occurs naturally in the human body and declines with age, which is part of why it’s drawn so much research interest in skin and anti-aging applications. It’s studied both topically and as an injectable research compound, and it’s available through research peptide suppliers across Canada.

What GHK-Cu Is Studied For

• Collagen and elastin production — GHK-Cu is studied for its role in signaling skin repair and remodeling processes
• Wound healing research — one of its longest-standing research applications
• Anti-aging and skin research — its natural decline with age is a major reason it’s studied in this context
• Hair-related research — some studies have examined GHK-Cu in the context of hair follicle activity

Why the Solution Turns Blue

If you’ve reconstituted GHK-Cu, you’ve probably noticed the solution takes on a pale blue tint. This is completely normal — it’s the color of the copper complex itself once dissolved, not a sign of contamination or a bad batch.

The “Copper Uglies” Explained

This is the most commonly asked question about GHK-Cu, and it deserves a straight answer: “copper uglies” is the community term for temporary skin flushing, redness, or a mild bruise-like discoloration that can appear at the injection site. It’s a cosmetic side effect related to the compound’s local effect on the skin, not a sign of a reaction requiring concern in most cases — but it’s real, it’s common enough to have its own nickname, and it’s worth knowing about before your first use rather than being caught off guard by it.

It typically fades on its own over a period of days. Rotating injection sites (the same practice covered in our general handling guide) tends to reduce how noticeable it is over time, since it prevents the effect from concentrating in one visible spot.

Research Considerations

GHK-Cu’s research base looks different from compounds like the GLP-1 family — there isn’t a large-scale pharmaceutical trial program behind it. Its research history is longer-standing and more decentralized, spanning decades of smaller studies in dermatology and wound-healing literature rather than a single headline clinical trial program. That’s worth understanding: “well-studied” doesn’t always mean “backed by one large trial,” and GHK-Cu is a good example of a compound where the research base is broad rather than concentrated.

Frequently Asked Questions

Is the blue color in reconstituted GHK-Cu normal? Yes — it’s the copper complex, not contamination.

How long do copper uglies last? Typically a matter of days, and rotating injection sites tends to make it less noticeable over repeated use.

Is GHK-Cu available as a research compound in Canada? Yes — GHK-Cu is available through research peptide suppliers in Canada as a laboratory research compound.

By Judith Wenshuk, peptide research writer

Quick Answer: Semaglutide is the most established compound in the GLP-1 family, with the longest clinical track record of the three major compounds in this category. Trial data (the STEP program) showed average weight loss of around 15% over 68 weeks at the maintenance dose, and it remains the benchmark that newer compounds like Tirzepatide and Retatrutide are measured against.

Semaglutide is where the modern GLP-1 research category effectively started, and it’s still the compound with the deepest body of published data behind it. It’s available in Canada both as a prescription medication and, separately, as a research compound through peptide suppliers.

How It Works

Semaglutide activates the GLP-1 receptor, a single mechanism that affects appetite regulation, gastric emptying, and blood sugar signaling. This single-receptor approach is what later compounds like Tirzepatide (dual-receptor) and Retatrutide (triple-receptor) were built to expand on — but it’s also why Semaglutide has by far the longest history of real-world data behind it.

Typical Research Protocol

The STEP trial program used a gradual escalation over roughly four months:

• Weeks 1–4: 0.25mg weekly
• Weeks 5–8: 0.5mg weekly
• Weeks 9–12: 1mg weekly
• Weeks 13–16: 1.7mg weekly
• Week 17 onward: 2.4mg weekly (studied maintenance dose)

This is a notably slower and more gradual escalation than either Tirzepatide or Retatrutide’s trial protocols, reflecting Semaglutide’s more conservative, longer-established dosing history.

What the Data Shows

In the STEP 1 trial, participants at the 2.4mg maintenance dose averaged approximately 15% weight loss over 68 weeks. That’s meaningfully lower than the headline numbers for Tirzepatide (20–22%) or Retatrutide (up to 28.7%) — but Semaglutide’s trial program is also the largest and longest-running of the three, with more real-world data supporting those numbers than either newer compound currently has.

What People Report

Compared to Tirzepatide and Retatrutide, Semaglutide is frequently described in research communities as the gentlest of the three in terms of side effects — generally less nausea during escalation — though also, consistent with the trial data, the mildest in terms of overall effect size. It’s often the starting point people choose when new to this category, precisely because of that more moderate profile.

How It Compares

For a full breakdown of Semaglutide against Tirzepatide and Retatrutide together, see our three-way comparison guide.

Frequently Asked Questions

Is Semaglutide weaker than Tirzepatide and Retatrutide? In terms of average trial weight-loss outcomes, yes — but it also has the longest safety and efficacy track record of the three.

Why does Semaglutide’s protocol take longer to reach maintenance dose? Its escalation schedule reflects an earlier, more conservative trial design compared to the newer compounds that followed it.

Is Semaglutide available as a research compound in Canada? Yes — Semaglutide is available through research peptide suppliers in Canada, separate from its prescription-drug availability.

By Judith Wenshuk, peptide research writer

Quick Answer: Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue, studied primarily for its effects on visceral fat and growth hormone signaling. It has a more established clinical history than most compounds in the growth-hormone research category, including FDA approval in a prescription form for a specific indication.

Tesamorelin stands apart from most growth-hormone-related research peptides because it already has real clinical approval behind it — not for general use, but for a specific, well-documented application, which gives it a stronger evidence base than most compounds in this category. It’s available in Canada through research peptide suppliers for laboratory study.

How It Works

Tesamorelin is a GHRH analogue — it doesn’t supply growth hormone directly, but instead signals the pituitary gland to increase the body’s own natural growth hormone release. This indirect mechanism is a key difference from compounds like HGH itself, which supply growth hormone directly rather than stimulating its release.

What the Data Shows

Tesamorelin’s clinical trial history centers on visceral fat reduction — the deeper abdominal fat associated with metabolic risk, as distinct from subcutaneous fat. Trial data supporting its approved use showed measurable reductions in visceral fat over a six-month treatment period, with effects generally reversing after discontinuation, which is consistent with its mechanism of stimulating natural growth hormone release rather than making a permanent structural change.

Typical Research Protocol

Clinical use is typically studied as a once-daily subcutaneous administration, in contrast to the once-weekly protocols common to the GLP-1 family. Trial durations extended to six months and beyond, since visceral fat changes were measured as a gradual effect rather than an early, rapid one.

How It Compares to Other Growth-Hormone Compounds

Tesamorelin is often discussed alongside CJC-1295 and Ipamorelin, since all three relate to growth hormone signaling through different mechanisms. We’ve written a full comparison covering how Tesamorelin stacks up against CJC-1295/Ipamorelin, and a broader three-way comparison including HGH itself.

Frequently Asked Questions

Is Tesamorelin the same as HGH? No — Tesamorelin stimulates the body’s own growth hormone release, while HGH is the hormone itself, administered directly.

Does the visceral fat reduction last after stopping? Trial data generally shows effects reversing over time after discontinuation, consistent with its mechanism of stimulating a natural process rather than a permanent change.

Is Tesamorelin available as a research compound in Canada? Yes — Tesamorelin is available through research peptide suppliers in Canada as a laboratory research compound.

By Judith Wenshuk, peptide research writer

Quick Answer: Tirzepatide is a dual-receptor compound that activates both GLP-1 and GIP receptors, studied primarily for its effects on appetite regulation and metabolic signaling. In clinical trials, it produced greater average weight loss than single-receptor GLP-1 compounds like semaglutide, with results building gradually over a multi-month dose escalation rather than appearing immediately.

Tirzepatide is one of the most-researched compounds in the GLP-1 family — approved in some markets as a prescription medication under brand names like Mounjaro and Zepbound, and available separately as a research compound for laboratory study in Canada. Here’s what the actual research shows.

How It Works

Most compounds in this category act on a single receptor — GLP-1. Tirzepatide is different: it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. Researchers believe this dual mechanism is what accounts for its stronger results compared to single-receptor compounds, since GIP and GLP-1 affect appetite and metabolic signaling through partially different pathways.

Typical Research Protocol

Clinical trials (the SURMOUNT series) used a gradual dose-escalation protocol, increasing every four weeks to allow the body to adjust:

• Weeks 1–4: 2.5mg weekly
• Weeks 5–8: 5mg weekly
• Weeks 9–12: 7.5mg weekly
• Weeks 13–16: 10mg weekly
• Weeks 17–20: 12.5mg weekly
• Week 21 onward: 15mg weekly (highest studied maintenance dose)

Not every trial participant escalated all the way to 15mg — the protocol allows stopping at whichever dose produces adequate results with manageable side effects, which is part of why trial data reports a range of outcomes rather than one fixed number.

What the Data Shows

In the SURMOUNT-1 trial, participants at the highest maintenance dose (15mg) averaged around 20–22% body weight reduction over 72 weeks — meaningfully higher than single-receptor GLP-1 compounds tested in comparable trial designs. Results built gradually: minimal change in the first few weeks, with the majority of weight change occurring after several months of consistent use at an established maintenance dose.

What People Report

Beyond the clinical trial numbers, Tirzepatide is frequently described in community discussion as producing the strongest appetite suppression of the three GLP-1 compounds — often reported as a much earlier and more complete drop in hunger compared to Semaglutide. This is anecdotal, self-reported experience rather than a head-to-head clinical measurement, but it’s a consistent enough pattern across independent reports that it’s worth mentioning alongside the trial data.

Commonly Reported Effects During Escalation

The most frequently reported effects during dose escalation are gastrointestinal — nausea, reduced appetite, and occasional digestive changes — and these tend to be most noticeable in the first week or two after each dose increase, then taper before the next increase. This is a large part of why the trial protocol escalates gradually rather than starting at the target dose.

How It Compares to Other GLP-1 Compounds

If you’re weighing Tirzepatide against Semaglutide or Retatrutide specifically, we’ve written full head-to-head comparisons for both.

Frequently Asked Questions

Is Tirzepatide the same as Semaglutide? No — they’re related but distinct compounds. Semaglutide activates only the GLP-1 receptor; Tirzepatide activates both GLP-1 and GIP.

How long before results are noticeable? Trial data shows minimal change in the first few weeks, with more significant changes typically building after two to three months at an established dose.

Is Tirzepatide available as a research compound in Canada? Yes — Tirzepatide is available through research peptide suppliers in Canada as a laboratory research compound, separate from its prescription-drug availability.

For Canadians comparing all three major GLP-1 research compounds side by side, our full comparison guide breaks down how Tirzepatide stacks up against Semaglutide and Retatrutide.

By Judith Wenshuk, peptide research writer

Quick Answer: Retatrutide is the newest and most powerful compound in the GLP-1 family, activating three receptors (GLP-1, GIP, and glucagon) instead of one or two. Phase 2 trial data showed an average of 24.2% weight loss over 48 weeks at the highest dose, with Phase 3 data pushing that as high as 28.7% — the strongest results of any compound in this category studied so far, available in Canada through research peptide suppliers.

Retatrutide has generated more interest than almost any other research peptide in the last two years, largely because its trial results have consistently outperformed every other compound in the GLP-1 family. Here’s what the actual data shows, and what Canadian researchers are reporting from real-world use.

How It Works

Where Semaglutide activates one receptor (GLP-1) and Tirzepatide activates two (GLP-1 and GIP), Retatrutide is a triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. The added glucagon activity is believed to be what pushes its results beyond the other two, since glucagon receptor activity is linked to increased energy expenditure in addition to the appetite effects shared with the other compounds.

Typical Research Protocol

Eli Lilly’s Phase 2 trial used a gradual four-dose escalation:

• Weeks 1–4: 2mg weekly
• Weeks 5–8: 4mg weekly
• Weeks 9–12: 8mg weekly
• Week 13 onward: 12mg weekly (highest studied dose)

As with other compounds in this category, the gradual escalation exists specifically to manage tolerability — jumping straight to a higher dose is associated with substantially more difficult side effects during the first weeks.

What the Data Shows

Phase 2 trial results at the 12mg dose averaged 24.2% weight loss over 48 weeks, with more than 80% of participants losing at least 15% of their starting body weight. Later Phase 3 data (the TRIUMPH trial program) pushed those numbers even further, with results up to 28.7% over a longer duration — alongside a notable secondary finding of liver fat reduction as high as 86% in some measurements, an effect that’s drawn separate research interest on its own.

What Canadian Researchers Report

Self-reported data from research communities tells a slightly different story than the trial numbers, which is worth knowing going in: real-world reports average closer to 15% weight change by month 6 and 18–22% by month 12 — still substantial, but somewhat below the controlled trial environment’s numbers, which is typical when comparing self-reported use to a monitored clinical trial. The most consistently reported side effect during escalation is nausea, and the most common tip shared across research communities is injecting before sleep, which several report makes the nausea considerably easier to manage.

How It Compares

If you’re deciding between Retatrutide and the other GLP-1 compounds, we’ve written full comparisons against both Tirzepatide and against Semaglutide and Tirzepatide together.

Frequently Asked Questions

Is Retatrutide stronger than Tirzepatide? Based on trial data, yes — Retatrutide’s triple-receptor mechanism has produced higher average weight loss than Tirzepatide’s dual-receptor mechanism in comparable trial designs.

Why does Retatrutide reduce liver fat specifically? This isn’t fully settled in the research yet, but it’s believed to relate to the added glucagon receptor activity, which affects metabolic processes beyond appetite alone.

Is Retatrutide available as a research compound in Canada? Yes — Retatrutide is available through research peptide suppliers in Canada, sold strictly for laboratory research.

By Judith Wenshuk, peptide research writer

Quick Answer: Beyond the basic trial protocol, most of what determines a smooth Retatrutide research experience comes down to titration pace, timing, and supporting habits like hydration and protein intake. This guide covers the practical side the overview doesn’t: what each phase of escalation typically involves, and what tends to make it easier or harder.

Our Retatrutide overview covers the mechanism and headline trial numbers. This guide is the practical follow-up — what actually happens phase by phase, and what tends to separate an easy escalation from a difficult one.

Conservative vs. Standard Escalation

The standard trial protocol escalates every four weeks (2mg → 4mg → 8mg → 12mg). Some research communities report using a slower, more conservative pace — extending each phase to six weeks instead of four — specifically to reduce nausea intensity during the transition points. There’s a real tradeoff here: a slower escalation takes longer to reach the studied maintenance dose, but several self-reported accounts describe it as meaningfully easier to tolerate.

What Each Phase Typically Involves

• Weeks 1–4 (2mg): Often described as the easiest phase — many report barely noticing an effect at this dose.
• Weeks 5–8 (4mg): Appetite changes usually become noticeable here — smaller portions feeling sufficient sooner.
• Weeks 9–12 (8mg): Commonly reported as the most difficult transition — nausea and food aversions are most frequently mentioned at this stage.
• Week 13 onward (12mg): By this point, most people who’ve tolerated the earlier phases report the nausea has largely settled, with appetite suppression well established.

Supporting Habits That Affect Tolerability

A few things are consistently mentioned across research communities as making escalation easier:

• Injecting before sleep — several report this significantly reduces next-day nausea compared to daytime injection
• Cold foods during difficult phases — things like yogurt or a protein shake straight from the fridge are frequently mentioned as more tolerable than warm meals when nausea is present
• Adequate protein intake — supporting lean mass during a period of reduced overall food intake
• Staying ahead of hydration — appetite-suppressing compounds in this category are associated with reduced thirst cues as well as reduced hunger, so hydration needs conscious attention rather than relying on thirst alone

Benefits Beyond Weight Change

The headline trial number is weight loss, but Retatrutide’s trial data also showed a notable secondary effect: liver fat reduction as high as 86% in some measurements. This has drawn separate research interest in its own right, independent of the weight-loss application.

Frequently Asked Questions

Is a slower escalation actually better? The trial protocol used four-week phases, but a slower, self-directed pace is a commonly reported approach for managing tolerability. Neither is “correct” — it’s a tradeoff between speed and comfort.

When do most people see real changes? Reported timelines vary, but the pattern across most accounts is minimal change in the first month, noticeable appetite changes by month two, and the most significant cumulative changes building over three to six months.

Does Retatrutide affect anything besides appetite? The liver fat findings suggest effects beyond appetite regulation alone, though this is an area of ongoing research rather than a settled conclusion.